60 Degrees Pharmaceuticals sponsors pre-clinical study of tafenoquine against Candida auris with Monash University

60 DEGREES PHARMACEUTICALS, INC.

Animal studies will test tafenoquine efficacy against Candida spp, including drug-resistant Candida auris.
Monash University conducts studies; experiments start May 2024, completion by Nov 30, 2024.
Company to pay Monash $90,167 AUD on April 1, 2024 and $90,167 AUD on service completion.
Tafenoquine is FDA-approved for malaria prophylaxis; its antifungal mode of action is differentiated from standard care.
Results expected by end of 2024; earlier in vitro data showed broad-spectrum antifungal activity.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

60 DEGREES PHARMACEUTICALS, INC. entered into Research Services Agreement with Monash University valued at $90,167 AUD on April 1, 2024 and $90,167 AUD upon the completion of the Services (effective 2024-02-05).

Action: entry
Counterparty: Monash University
Value: $90,167 AUD on April 1, 2024 and $90,167 AUD upon the completion of the Services
Effective: 2024-02-05

Exact text from the filing

On February 13, 2024, 60 Degrees Pharmaceuticals, Inc.’s (the “Company”) majority-owned Australian subsidiary, 60P Australia Pty Ltd, and Monash University entered into the Research Services Agreement (the “Agreement”) in which Monash University agreed to provide research services, including among other things, testing the efficacy of tafenoquine against candidemia, confirming suitable fungal infection dosage and determining the pharmacokinetics of tafenoquine following intraperitoneal drug administration (collectively, the “Services”).

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

60 DEGREES PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-24-015295

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.